CD274 and neoplasm: In another phase 3 trial (KEYNOTE-024) with 305 advanced NSCLC patients who were not previously treated and had no sensitizing mutation for target therapies in their tumors but had at least 50% PD-L1+ tumor cells, patients were randomly assigned to the treatment with either pembrolizumab (200 mg every 3 weeks) or platinum-based chemotherapy [22].